Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of japanese encephalitis viral infection

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Sehgal, Neha ^a   Kumawat, Kanhaiya Lal ^a   Basu, Anirban ^a   Ravindranath, Vijayalakshmi ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOCHROME P450; CYTOCHROME P450 F13; CYTOCHROME P450 F14; CYTOCHROME P450 F15; CYTOCHROME P450 F16; CYTOCHROME P450 F18; CYTOKINE; FENOFIBRATE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DETOXIFICATION; GENE SEQUENCE; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MICROGLIA; MORTALITY; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; SURVIVOR; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; DRUG POTENTIATION; METABOLISM; VIROLOGY;

FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; MURINAE; MUS;

ANIMALS; CHEMOKINES; CYTOKINES; EICOSANOIDS; ENCEPHALITIS, JAPANESE; FENOFIBRATE; LEUKOTRIENE B4; MICE; MICE, INBRED BALB C; NF-KAPPA B; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA;

EID: 84859710724     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035427     Document Type: Article

References (55)

1. Kumar R, Agarwal SP, Wakhlu I, Mishra KL, (1991) Japanese encephalitis-an encephalomyelitis. Indian Pediatr 28: 1525-1528.
2. Chen CJ, Raung SL, Kuo MD, Wang YM, (2002) Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol 83: 1897-1905.
3. Ghosh D, Basu A, (2009) Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis 3: e437.
4. Kumar R, Mathur A, Singh KB, Sitholey P, Prasad M, et al. (1993) Clinical sequelae of Japanese encephalitis in children. Indian J Med Res 97: 9-13.
5. Desai A, Shankar SK, Ravi V, Chandramuki A, Gourie-Devi M, (1995) Japanese encephalitis virus antigen in the human brain and its topographic distribution. Acta Neuropathol 89: 368-373.
6. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, et al. (2007) Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55: 483-496.
7. Mishra MK, Basu A, (2008) Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J Neurochem 105: 1582-1595.
8. Winter PM, Dung NM, Loan HT, Kneen R, Wills B, et al. (2004) Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis 190: 1618-1626.
9. Block ML, Zecca L, Hong JS, (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
10. Azab AN, Kaplanski J, (2004) Involvement of eicosanoids in the hypothermic response to lipopolysaccharide during endotoxemia in rats. Prostaglandins Leukot Essent Fatty Acids 70: 67-75.
11. Funk CD, (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
12. Kalsotra A, Anakk S, Brommer CL, Kikuta Y, Morgan ET, et al. (2007) Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Arch Biochem Biophys 461: 104-112.
13. Daynes RA, Jones DC, (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-759.
14. Stahel PF, Smith WR, Bruchis J, Rabb CH, (2008) Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008: 538141.
15. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, et al. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34: 1341-1346.
16. Youssef J, Badr M, (2004) Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. J Biomed Biotechnol 2004: 156-166.
17. Gray E, Ginty M, Kemp K, Scolding N, Wilkins A, (2011) Peroxisome proliferator-activated receptor-alpha agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. Eur J Neurosci 33: 1421-1432.
18. Deplanque D, Gele P, Petrault O, Six I, Furman C, et al. (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23: 6264-6271.
19. Tsimihodimos V, Liberopoulos E, Elisaf M, (2009) Pleiotropic effects of fenofibrate. Curr Pharm Des 15: 517-528.
20. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, et al. (2007) Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 24: 1119-1131.
21. Sehgal N, Agarwal V, Valli RK, Joshi SD, Antonovic L, et al. (2011) Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation. Biochem Pharmacol 82: 53-64.
22. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
23. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR, (2004) Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 146: 209-215.
24. Chomczynski P, (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15: 532-534 536-537.
25. Vrati S, Agarwal V, Malik P, Wani SA, Saini M, (1999) Molecular characterization of an Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. J Gen Virol 80 (Pt 7): 1665-1671.
26. Thongtan T, Cheepsunthorn P, Chaiworakul V, Rattanarungsan C, Wikan N, et al. (2010) Highly permissive infection of microglial cells by Japanese encephalitis virus: a possible role as a viral reservoir. Microbes Infect 12: 37-45.
27. Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, et al. (2011) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer.
28. Cree MG, Zwetsloot JJ, Herndon DN, Qian T, Morio B, et al. (2007) Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 245: 214-221.
29. Choi JH, Shin YL, Kim GH, Hong SJ, Yoo HW, (2006) Treatment of hyperlipidemia associated with Niemann-Pick disease type B by fenofibrate. Eur J Pediatr 165: 138-139.
30. Wu J, Song Y, Li H, Chen J, (2009) Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 65: 1169-1174.
31. Tahmaz M, Kumbasar B, Ergen K, Ure U, Karatemiz G, et al. (2007) Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Ren Fail 29: 927-930.
32. Archambeaud-Mouveroux F, Lopez S, Combes C, Lassandre S, Amaniou M, et al. (2006) [Rhabdomyolysis induced by fenofibrate monotherapy]. Rev Med Interne 27: 573-574.
33. Barker BJ, Goodenough RR, Falko JM, (2003) Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 26: 2482-2483.
34. Ramazan D, Sami A, Sehmus O, Senay A, (2010) Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. Case Reports in Medicine 2010.
35. Elsayed EF, Reilly RF, (2010) Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol 25: 7-18.
36. Berger J, Moller DE, (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
37. Corton JC, Anderson SP, Stauber A, (2000) Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40: 491-518.
38. Fruchart JC, (2009) Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205: 1-8.
39. Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH, (2008) Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 124: 149-159.
40. Fruchart JC, Staels B, Duriez P, (2001) PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44: 345-352.
41. Wang G, Liu X, Guo Q, Namura S, (2010) Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels. Brain Res 1359: 247-255.
42. Arnaiz SL, Travacio M, Llesuy S, Boveris A, (1995) Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1272: 175-180.
43. Vanden Berghe W, Vermeulen L, Delerive P, de Bosscher K, Staels B, et al. (2003) A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 544: 181-196.
44. Delerive P, Gervois P, Fruchart JC, Staels B, (2000) Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275: 36703-36707.
45. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, et al. (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384: 39-43.
46. Kalsotra A, Strobel HW, (2006) Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther 112: 589-611.
47. Wang Y, Zhao J, Kalsotra A, Turman CM, Grill RJ, et al. (2008) CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury. J Neurotrauma 25: 1187-1194.
48. Mehl JK, Witiak DT, Hamparian VV, Hughes JH, (1980) Antiviral activity of antilipidemic compounds on herpes simplex virus type 1. Antimicroblal agents and chemotherapy 18: 269-275.
49. Skolnik PR, Rabbi MF, Mathys JM, Greenberg AS, (2002) Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. J Acquir Immune Defic Syndr 31: 1-10.
50. Halstead SB, Thomas SJ, (2010) New vaccines for Japanese encephalitis. Curr Infect Dis Rep 12: 174-180.
51. Wilder-Smith A, Halstead SB, (2010) Japanese encephalitis: update on vaccines and vaccine recommendations. Curr Opin Infect Dis 23: 426-431.
52. Wei JC, Huang YZ, Zhong DK, Kang L, Ishag H, et al. (2010) Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice. Biochem Biophys Res Commun 396: 787-792.
53. Wilson ME, (2009) Japanese encephalitis: new vaccines. Curr Infect Dis Rep 11: 37-39.
54. Bharati K, Vrati S, (2006) Japanese encephalitis: development of new candidate vaccines. Expert Rev Anti Infect Ther 4: 313-324.
55. Kaur R, Vrati S, (2003) Development of a recombinant vaccine against Japanese encephalitis. J Neurovirol 9: 421-431.